Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir study, Thailand

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Martin, Michael ^a,b   Vanichseni, Suphak ^c   Suntharasamai, Pravan ^c   Sangkum, Udomsak ^c   Chuachoowong, Rutt ^a   Mock, Philip A ^a   Leethochawalit, Manoj ^d   Chiamwongpaet, Sithisat ^d   Kittimunkong, Somyot ^e   van Griensven, Frits ^a   McNicholl, Janet M ^a,b   Paxton, Lynn ^b   Choopanya, Kachit ^c  

^a Centers for Disease Control CDC Thailand Field Station   (Thailand)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Bangkok Tenofovir Study Group   (Thailand)

^d Bangkok Metropolitan Administration   (Thailand)

^e MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

DIAMORPHINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; METHADONE; METHAMPHETAMINE; MIDAZOLAM; PLACEBO; TENOFOVIR DISOPROXIL; ADENINE; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ADULT; ARTICLE; CONDOM; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EDUCATION; FEMALE; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRISONER; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SEXUAL INTERCOURSE; THAILAND; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; INFECTION CONTROL; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RISK; SUBSTANCE ABUSE;

ADENINE; ADMINISTRATION, ORAL; ADULT; AIDS VACCINES; COMMUNICABLE DISEASE CONTROL; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PLACEBOS; RISK; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS; THAILAND;

EID: 80053232795     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025127     Document Type: Article

References (44)

1. Weniger BG, Limpakarnjanarat K, Ungchusak K, Thanprasertsuk S, Choopanya K, et al. (1991) The epidemiology of HIV infection and AIDS in Thailand. AIDS 5 (Suppl. 2): S71-S85.
2. National AIDS Prevention and Alleviation Committee UNGASS Country Progress Report, Thailand. Thailand Ministry of Public Health, Department of Disease Control. Available: http://data.unaids.org/pub/report/2008/thailand_2008_country_progress_report_en.pdf Accessed 2011 May 26.
3. WHO Epidemiological Fact Sheet on HIV and AIDS, Thailand, 2008 update. Available: http://apps.who.int/globalatlas/predefinedReports/EFS2008/full/EFS2008_TH.pdf Accessed 2011 May 26.
4. De Clercq E, Sakuma T, Baba M, Pauwels R, Balzarini J, et al. (1987) Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res 8: 261-272.
5. De Clercq E, (2003) Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections. Clin Microbiol Rev 16: 569-596.
6. Gallant JE, Deresinski S, (2003) Tenofovir disoproxil fumarate. Clin Infect Dis 37: 944-950.
7. Gilead Sciences Viread (tenofovir disoproxil fumarate) tablets [full prescribing information] 2010 Foster City, California Gilead Sciences Available: http://www.gilead.com/pdf/viread_pi.pdf. Accessed 2011 May 26.
8. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, et al. (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. JAMA 292: 191-201.
9. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, et al. (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354: 251-260.
10. Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, et al. (1999) In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 4: 87-94.
11. Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ, et al. (2009) Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934. J Acquir Immune Defic Syndr 52: 209-21.
12. Kearney BP, Isaacson E, Satre J, Cheng AK, (2003) Tenofovir DF and oral contraceptives: Lack of a pharmacokinetic drug interaction [Abstract A-1618]. Intersci Conf Antimicrob Agents Chemother. Available: http://gateway.nlm.nih.gov/MeetingAbstracts/ma?f=102265007.html. Accessed 2011 August 26.
13. Smith P, Kearney BP, Liaw S, Cloen D, Bullock JM, et al. (2004) Effect of Tenofovir Disoproxil Fumarate on the Pharmacokinetics and Pharmacodynamics of Total, R-, and S-Methadone. Pharmacotherapy 24: 970-977.
14. Tsai CC, Follis KE, Sabo A, Beck TW, Grant RF, et al. (1995) Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine. Science 270: 1197-1199.
15. Subbarao S, Otten RA, Ramos A, Kim C, Jackson E, et al. (2006) Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis 194: 904-911.
16. van Rompay KKA, Kearney BP, Sexton JJ, Colon R, Lawson JR, et al. (2006) Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus. J Acquir Immune Defic Syndr 43: 6-14.
17. García-Lerma JG, Otten RA, Qari SH, Jackson E, Cong M-e, et al. (2008) Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent Prophylaxis with Emtricitabine and Tenofovir. PLoS Med 5: e28 doi:10.1371/journal.pmed.0050028.
18. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. pp. 1-117 Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. May 24, 2010 Available: http://www.aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf Accessed 2011 May 26.
19. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, et al. (1997) A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 337: 1485-90.
20. CDC (2005) Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis. MMWR 54 (RR-9): 1-17.
21. Chuachoowong R, Martin M, Prasitiphol B, Vanichseni S, Suntharasamai P, et al. (2008) Involving communities to inform an HIV prevention trial in Bangkok [Abstract WEPE0262]. The 17th International AIDS Conference 2008, Mexico City. Available: http://www.aids2008.org/Pag/Abstracts.aspx?AID=4362. Accessed 2011 May 26.
22. Vanichseni S, Kitayaporn D, Mastro TD, Mock PA, Raktham S, et al. (2001) Continued high HIV-1 incidence in a vaccine trial preparatory cohort of injection drug users in Bangkok, Thailand. AIDS 15: 397-405.
23. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, et al. (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194: 1661-71.
24. Karim QA, Karim SSA, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. Science 326: 1168-1174.
25. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. NEJM 363: 2587-99.
26. FHI FEM-PrEP Project. Available: http://www.fhi360.org/en/Research/Projects/FEM-PrEP.htm. Accessed 2011 August 22.
27. Thigpen MC, Kebaabetswe PM, Smith DK, Segolodi TM, Soud FA, et al. (2011) Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. [Abstract WELBC01]. The 6th International AIDS Society Conference. Available: http://pag.ias2011.org/abstracts.aspx?aid=4631. Accessed 2011 August 22.
28. Baeten J, (2011) Antiretroviral Pre-Exposure Prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP Study [Abstract MOAX0106]. The 6th International AIDS Society Conference. Available: http://pag.ias2011.org/flash.aspx?pid=886. Accessed 2011 August 22.
29. Suntharasamai P, Martin M, Vanichseni S, van Griensven F, Mock PA, et al. (2009) Factors associated with incarceration and incident HIV infection among injection drug users participating in an HIV vaccine trial in Bangkok, Thailand, 1999-2003. Addiction 104: 235-242.
30. Vanichseni S, Tappero JW, Pitisuttithum P, Kitayaporn D, Mastro TD, et al. (2004) Recruitment, screening and characteristics of injection drug users participating in the AIDSVAX® B/E HIV vaccine trial, Bangkok, Thailand. AIDS 18: 311-6.
31. van Griensven F, Keawkungwal J, Tappero JW, Sangkum U, Pitisuttithum P, et al. (2004) Lack of increased HIV risk behavior among injection drug users participating in the AIDSVAX B/E HIV vaccine trial in Bangkok, Thailand. AIDS 18: 295-301.
32. van Griensven F, Pitisuttithum P, Vanichseni S, Wichienkuer P, Tappero JW, et al. (2005) Trends in the injection of midazolam and other drugs and needle sharing among injection drug users enrolled in the AIDSVAX B/E HIV-1 vaccine trial in Bangkok, Thailand. Int J Drug Policy 16: 171-5.
33. Martin M, Vanichseni S, Suntharasamai P, Mock PA, van Griensven F, et al. (2010) Drug use and the risk of HIV infection amongst injection drug users participating in an HIV vaccine trial in Bangkok, 1999-2003. Int J Drug Policy 21: 296-301.
34. Human Rights Watch (2004) Not Enough Graves: The War on Drugs, HIV/AIDS, and Violations of Human Rights. Human Rights Watch Report; 16:No. 8(C). Available: http://www.hrw.org/reports/2004/thailand0704/index.htm Accessed 2011 May 26.
35. Vongchak T, Kawichai S, Sherman S, Celentano DD, Sirisanthana T, et al. (2005) The influence of Thailand's 2003 'war on drugs' policy on self-reported drug use among injection drug users in Chiang Mai, Thailand. International Journal of Drug Policy 16: 115-121.
36. Mastro TD, Kitayapom D, Weniger BG, Vanichseni S, Laosunthom V, et al. (1994) Estimating the Number of HIV-Infected Injection Drug Users in Bangkok: A Capture-Recapture Method. Am J Public Health 84: 1094-1099.
37. Wattana W, van Griensven F, Rhucharoenpornpanich O, Manopaiboon C, Thienkrua W, et al. (2007) Respondent-driven sampling to assess characteristics and estimate the number of injection drug users in Bangkok, Thailand. Drug and Alcohol Dependence 90: 228-233.
38. Choopanya K, Des Jarlais DC, Vanichseni S, Kitayaporn D, Mock PA, et al. (2002) Incarceration and risk for HIV infection among injection drug users in Bangkok. JAIDS 29: 86-94.
39. Mirin SM, Meyer RE, Mendelson JH, Ellingboe J, (1980) Opiate use and sexual function. Am J Psychiatry 137: 909-15.
40. Daniell HW, (2002) Narcotic-induced hypogonadism during therapy for heroin addiction. J Addict Dis 21: 47-53.
41. Konings E, Bantebya G, Caraël M, Bagenda D, Mertens T, (1995) Validating population surveys for the measurement of HIV/STD prevention indicators. AIDS 9: 375-82.
42. van Griensven F, Naorat S, Kilmarx PH, Jeeyapant S, Manopaiboon C, et al. (2006) Palmtop-assisted Self-Interviewing for the Collection of Sensitive Behavioral Data: Randomized Trial with Drug Use Urine Testing. Am J Epidemiol 163: 271-8.
43. Des Jarlais DC, Paone D, Milliken J, Turner CF, Miller H, et al. (1999) Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. Lancet 353: 1657-61.
44. Metzger DS, Koblin B, Turner C, Navaline H, Valenti F, et al. (2000) Randomized controlled trial of audio computer-assisted self-interviewing: utility and acceptability in longitudinal studies. Am J Epidemiol 152: 99-106.